A total of 156/400 patients in the dapagliflozin group (39.0%) and 182/401 patients in the glipizide group (45.4%) discontinued participation in the study because of lack of glycaemic control or required rescue therapy.Glipizide was associated with agreater probability of discontinuation because of lack of glycaemic